Product Description
Mechanisms of Action: VEGFR1 Inhibitor,VEGFR2 Inhibitor,VEGFR3 Inhibitor,PGFR Inhibitor,KITl Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Pleural Cancer|Pleural Effusion|Pericardial Effusion
Phase 2: Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Islet Cell Adenoma|Breast Cancer|Oncology Solid Tumor Unspecified|Gastrointestinal Stromal Tumors|Carcinoid Tumor|Malignant Carcinoid Syndrome|Neuroendocrine Tumors|Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer|Thyroid Cancer
Phase 1: Oncology Solid Tumor Unspecified|Lymphoproliferative Disorders|Pancreatic Cancer|Lung Cancer|Lymphoma|Esophageal Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 10G.30 | P2 |
Withdrawn |
Breast Cancer |
2015-09-01 |
|
| CDR0000526256 | P2 |
Completed |
Neuroendocrine Tumors|Islet Cell Adenoma|Gastrointestinal Cancer|Carcinoid Tumor|Malignant Carcinoid Syndrome |
2014-10-01 |
|
| Asian Phase 3 Study | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2014-09-01 |
|
| GOG-0170L | P2 |
Terminated |
Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
2013-07-01 |